About Roche

Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders, and most importantly, our patients remains as strong as it was on the first day of our journey.

Roche Pakistan Limited is part of the International F. Hoffmann-La Roche Group that was founded in 1896 in Basel, Switzerland. Roche has grown from a small drug laboratory into one of the world's leading research-based healthcare companies and is known for many innovative contributions to medicine.

Roche products were available in the Indian sub-continent much before Partition. After Pakistan emerged on the world map, imports continued and after a few years some products started to be manufactured in Karachi. In 1984, the foundation of the Roche plant was laid in the Korangi Industrial Area on the outskirts of Karachi. Within a span of three years the plant was constructed and Roche Pakistan started local manufacturing in October 1987.

In recent years, as Roche Pakistan's strategic focus moved towards its biotechnology medicines meant for the treatment of cancer, hematology and rare diseases, most of the traditional Pharmaceutical business along with the factory were divested in 2010.

Today, Roche Pakistan’s business covers both Pharmaceuticals and Diagnostics. In the Pharma market, Roche is ranked among the top companies, while in the Diagnostic sector, Roche is the market leader. The combined strengths of our Diagnostics and Pharmaceutical businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients' needs. Roche's products and services address the entire  healthcare spectrum, from screening for genetic risk factors to preventing, diagnosing and treating disease and monitoring the treatment response.

At Roche, we believe there is an urgent need to address the huge inequities in access to healthcare around the world, especially in countries like ours.The burden of expenses, especially for non-communicable diseases like cancer and rare diseases, looms large. We know that countless patients are unable to secure adequate medical treatment due to financial constraints. We also recognise that we have a responsibility to do something about it. Hence in 2017, we launched our Patient Support Program, UNMOL.

UNMOL, an Urdu term meaning 'precious,' is a dynamic Patient Support Program that aims to improve access to healthcare for the underprivileged by offering a sustainable financial solution for those in need of treatment. UNMOL seeks to support patients by contributing to the cost of treatment by providing free of cost medicines through partnerships and public funding programs.

Company Profile

Status of the Company: Public Unlisted Company

Company Registration Number: 0001857

Company NTN Number: 0711885-6 

Name of Auditor:  KPMG Taseer Hadi & Co.

Name of Legal Advisor: Vellani & Vellani, Fazleghani Associates

Shareholding Pattern:   Wholly owned subsidiary of Roche Holding Limited, Switzerland

Board of Directors: Hafsa Shamsie, Farhan Bhatti, Badaruddin F. Vellani

Discover more


This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsRoche careersPrivacy StatementLegal Statement